Zabofloxacin was
discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for
development.[6]
A double-blind, three-arm clinical study of the drug began in March 2010.[7]
References
^HyeKyung Han; Sung Eun Kim; Kwang-Hee Shin; Cheolhee Lim; Kyoung Soo Lim; Kyung-Sang Yu; Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion. 29 (10): 1349–1355.
doi:
10.1185/03007995.2013.825591.
PMID23865727.
S2CID11071210.
^Jong-Hwa Lee; Jung-Heun Ha; Dae-Hun Park; Dong-Rack Choi; Gye-Won Lee; Sung-Hoon Ahn & Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies. 37 (3): 311–320.
doi:
10.1080/10826076.2012.745137.
S2CID96104286.
^Kim EJ, Shin WH, Kim KS, Han SS (Nov 2004). "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol. 27 (4): 295–307.
doi:
10.1081/DCT-200039708.
PMID15573468.
S2CID13284436.